DNMT3A and myelodysplastic syndrome: DNA methyltransferase 3 A (DNMT3A) mutations are the most frequent alterations in de novo AML (20–25%), MDS (about 10%), and clonal hematopoiesis of indeterminate potential (CHIP), and are mostly heterozygous [67].